(JNJ) Johnson & Johnson - Overview
Stock: Immunology, Oncology, Cardiovascular, Orthopaedics, Contact Lenses
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 3.02% |
| Yield on Cost 5y | 4.50% |
| Yield CAGR 5y | 5.24% |
| Payout Consistency | 87.9% |
| Payout Ratio | 41.4% |
| Risk 5d forecast | |
|---|---|
| Volatility | 16.5% |
| Relative Tail Risk | -4.10% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 2.39 |
| Alpha | 55.00 |
| Character TTM | |
|---|---|
| Beta | 0.068 |
| Beta Downside | 0.084 |
| Drawdowns 3y | |
|---|---|
| Max DD | 15.95% |
| CAGR/Max DD | 1.11 |
Description: JNJ Johnson & Johnson January 28, 2026
Johnson & Johnson (NYSE: JNJ) operates globally in two core segments: Innovative Medicine, which develops prescription drugs across immunology, infectious disease, neuroscience, oncology, cardiovascular/metabolism, and pulmonary hypertension; and MedTech, which supplies electrophysiology, cardiovascular, neurovascular, orthopaedic, surgical, and vision-care devices. The company’s distribution network reaches wholesalers, hospitals, retailers, and clinicians, reflecting its integrated, end-to-end healthcare model.
As of the FY 2023 fiscal year, JNJ reported total revenue of $95.0 billion, with the Innovative Medicine segment contributing roughly $55 billion and MedTech $23 billion. R&D expenditure reached $14.2 billion (≈15% of revenue), supporting a pipeline that includes the PD-1 inhibitor
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 26.80b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA -0.94 > 1.0 |
| NWC/Revenue: 3.97% < 20% (prev 6.27%; Δ -2.30% < -1%) |
| CFO/TA 0.13 > 3% & CFO 24.20b > Net Income 26.80b |
| Net Debt (45.80b) to EBITDA (38.07b): 1.20 < 3 |
| Current Ratio: 1.07 > 1.5 & < 3 |
| Outstanding Shares: last quarter (2.44b) vs 12m ago 0.49% < -2% |
| Gross Margin: 72.78% > 18% (prev 0.69%; Δ 7209 % > 0.5%) |
| Asset Turnover: 50.52% > 50% (prev 49.32%; Δ 1.20% > 0%) |
| Interest Coverage Ratio: 50.90 > 6 (EBITDA TTM 38.07b / Interest Expense TTM 553.0m) |
Altman Z'' 3.97
| A: 0.02 (Total Current Assets 54.61b - Total Current Liabilities 50.87b) / Total Assets 192.82b |
| B: 0.87 (Retained Earnings 167.28b / Total Assets 192.82b) |
| C: 0.15 (EBIT TTM 28.14b / Avg Total Assets 186.46b) |
| D: 0.0 (Book Value of Equity 0.0 / Total Liabilities 113.54b) |
| Altman-Z'' Score: 3.97 = AA |
What is the price of JNJ shares?
Over the past week, the price has changed by +5.61%, over one month by +17.19%, over three months by +29.17% and over the past year by +61.12%.
Is JNJ a buy, sell or hold?
- StrongBuy: 7
- Buy: 4
- Hold: 13
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the JNJ price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 231.3 | -3.6% |
| Analysts Target Price | 231.3 | -3.6% |
| ValueRay Target Price | 285.2 | 18.8% |
JNJ Fundamental Data Overview February 07, 2026
P/E Forward = 20.3252
P/S = 6.0823
P/B = 7.1257
P/EG = 1.2699
Revenue TTM = 94.19b USD
EBIT TTM = 28.14b USD
EBITDA TTM = 38.07b USD
Long Term Debt = 39.41b USD (from longTermDebt, two quarters ago)
Short Term Debt = 6.39b USD (from shortTermDebt, two quarters ago)
Debt = 45.80b USD (from shortLongTermDebtTotal, two quarters ago)
Net Debt = 45.80b USD (using Total Debt 45.80b, CCE unavailable)
Enterprise Value = 618.70b USD (572.91b + Debt 45.80b - (null CCE))
Interest Coverage Ratio = 50.90 (Ebit TTM 28.14b / Interest Expense TTM 553.0m)
EV/FCF = 32.45x (Enterprise Value 618.70b / FCF TTM 19.06b)
FCF Yield = 3.08% (FCF TTM 19.06b / Enterprise Value 618.70b)
FCF Margin = 20.24% (FCF TTM 19.06b / Revenue TTM 94.19b)
Net Margin = 28.46% (Net Income TTM 26.80b / Revenue TTM 94.19b)
Gross Margin = 72.78% ((Revenue TTM 94.19b - Cost of Revenue TTM 25.64b) / Revenue TTM)
Gross Margin QoQ = 86.37% (prev 69.56%)
Tobins Q-Ratio = 3.21 (Enterprise Value 618.70b / Total Assets 192.82b)
Interest Expense / Debt = 0.05% (Interest Expense 23.0m / Debt 45.80b)
Taxrate = 17.73% (5.78b / 32.58b)
NOPAT = 23.15b (EBIT 28.14b * (1 - 17.73%))
Current Ratio = 1.07 (Total Current Assets 54.61b / Total Current Liabilities 50.87b)
Debt / Equity = 0.58 (Debt 45.80b / totalStockholderEquity, two quarters ago 79.28b)
Debt / EBITDA = 1.20 (Net Debt 45.80b / EBITDA 38.07b)
Debt / FCF = 2.40 (Net Debt 45.80b / FCF TTM 19.06b)
Total Stockholder Equity = 76.84b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.38% (Net Income 26.80b / Total Assets 192.82b)
RoE = 34.88% (Net Income TTM 26.80b / Total Stockholder Equity 76.84b)
RoCE = 24.21% (EBIT 28.14b / Capital Employed (Equity 76.84b + L.T.Debt 39.41b))
RoIC = 18.06% (NOPAT 23.15b / Invested Capital 128.22b)
WACC = 5.72% (E(572.91b)/V(618.70b) * Re(6.17%) + D(45.80b)/V(618.70b) * Rd(0.05%) * (1-Tc(0.18)))
Discount Rate = 6.17% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 33.33 | Cagr: 0.17%
[DCF Debug] Terminal Value 86.25% ; FCFF base≈19.24b ; Y1≈19.07b ; Y5≈19.83b
Fair Price DCF = 226.8 (EV 592.19b - Net Debt 45.80b = Equity 546.40b / Shares 2.41b; r=5.90% [WACC]; 5y FCF grow -1.62% → 2.90% )
EPS Correlation: 14.01 | EPS CAGR: -2.16% | SUE: 0.0 | # QB: 0
Revenue Correlation: 11.28 | Revenue CAGR: 1.27% | SUE: 1.56 | # QB: 1
EPS next Quarter (2026-03-31): EPS=2.69 | Chg30d=-0.057 | Revisions Net=+0 | Analysts=16
EPS current Year (2026-12-31): EPS=11.53 | Chg30d=+0.010 | Revisions Net=+4 | Growth EPS=+6.9% | Growth Revenue=+6.8%
EPS next Year (2027-12-31): EPS=12.55 | Chg30d=+0.154 | Revisions Net=+12 | Growth EPS=+8.8% | Growth Revenue=+5.1%